吉林敖东(000623) - 2021 Q2 - 季度财报

Financial Performance - The company's operating revenue for the first half of 2021 was ¥1,082,746,445.65, a decrease of 3.45% compared to ¥1,121,445,607.54 in the same period last year[12]. - The net profit attributable to shareholders of the listed company was ¥962,283,316.78, down 5.67% from ¥1,020,099,858.24 in the previous year[12]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥1,040,667,183.37, a slight decrease of 0.37% compared to ¥1,044,491,211.06 last year[12]. - The net cash flow from operating activities was ¥269,979,631.46, representing a decline of 19.74% from ¥336,388,321.86 in the same period last year[12]. - Basic earnings per share were ¥0.84, down 4.55% from ¥0.88 in the previous year[12]. - Diluted earnings per share were ¥0.81, a decrease of 3.57% compared to ¥0.84 last year[12]. - The weighted average return on net assets was 4.06%, down from 4.50% in the previous year, a decrease of 0.44%[12]. - The total profit amounted to 949.78 million yuan, down by 74.49 million yuan, which is a year-on-year decrease of 7.27%[20]. - Revenue from the pharmaceutical sector was ¥871,343,034.74, accounting for 80.48% of total revenue, down 10.91% from ¥977,998,133.85[38]. - The company reported a significant increase in technology service fees contributing to other business income[41]. Assets and Liabilities - Total assets at the end of the reporting period were ¥28,285,485,428.68, an increase of 3.41% from ¥27,353,457,083.87 at the end of the previous year[12]. - The net assets attributable to shareholders of the listed company were ¥23,940,426,826.19, up 2.52% from ¥23,353,020,520.01 at the end of the previous year[12]. - The asset-liability ratio stood at 14.71%[20]. - Cash and cash equivalents decreased by 40.85% to ¥1,481,159,887.51, accounting for 5.24% of total assets[42]. - Accounts receivable increased by 24.66% to ¥673,857,351.66, representing 2.38% of total assets[42]. - Inventory rose by 11.77% to ¥613,036,151.61, making up 2.17% of total assets[42]. - Long-term equity investments increased by 2.09% to ¥18,176,160,507.64, comprising 64.26% of total assets[42]. - Total liabilities reached CNY 4.16 billion, up from CNY 3.82 billion, indicating a growth of around 8.9%[91]. Research and Development - The company continues to leverage its "industry-university-research collaborative innovation mechanism" to enhance R&D investment, focusing on the development of new varieties and the secondary development of major products[22]. - The company is actively exploring and optimizing classic traditional Chinese medicine formulas and standards for medicinal materials[23]. - The company is conducting preclinical research on Bai Lian Shen granules, which are intended for adjuvant therapy in lung cancer[24]. - The company is in the process of confirming the process for the production of five new products, including the oral liquid for diabetes (XMFWG001), which has submitted application materials and is under review by the national bureau[24]. - The company is focusing on the development of Best-in-class and First-in-class drugs targeting significant clinical needs[22]. - The company is committed to improving the quality and efficiency of its pharmaceutical products through continuous R&D efforts[22]. Investments - Investment income from Guangfa Securities for the period was 1.06 billion yuan, an increase of 55.93 million yuan, or 5.55% year-on-year[20]. - The company actively invests in various funds, including a 200 million yuan contribution to the Aodong Pharmaceutical Fund, accounting for 40% of the total fund[21]. - The company holds a 17.5752% stake in GF Securities, which reported a net profit of CNY 6,476,893,317.32, indicating strong performance in the securities brokerage sector[49]. - The investment in the fund "Guangfa Core Selected Mixed" generated a profit of CNY 323,871.23 during the reporting period[47]. Corporate Governance - The annual shareholders' meeting had a participation rate of 34.93%, reflecting investor engagement in corporate governance[52]. - The company does not plan to distribute cash dividends or issue new shares from capital reserves for the half-year period[53]. - The employee stock ownership plan was established in 2016, with 19,809,743 shares transferred to the plan's account[54]. - The employee stock ownership plan holds a total of 2,575.27 million shares, with 86.08% held by employees[55]. - The chairman, Li Xiulin, holds 182.00 million shares, representing 7.07% of the total stock ownership plan[55]. Environmental Compliance - The company has reported a total COD discharge of 1.62 tons, which is below the approved discharge limit of 2.437 tons[59]. - The company has implemented online monitoring equipment to ensure compliance with environmental discharge standards[61]. - There were no administrative penalties related to environmental issues during the reporting period[63]. - The company actively integrates ecological and environmental protection requirements into its development strategy[63]. Financial Reporting - The half-year financial report was not audited, indicating a potential area for future scrutiny[65]. - The financial statements are prepared in accordance with the relevant accounting standards and reflect the company's financial status accurately[122]. - The company has implemented specific accounting policies based on its operational characteristics, ensuring compliance with accounting standards[120]. Share Capital and Dividends - The company completed a share repurchase plan, acquiring 24,220,987 shares, which is 2.08% of the total share capital as of March 31, 2021[74]. - The maximum purchase price for the repurchased shares was set at RMB 20.00 per share, with actual prices ranging from RMB 15.05 to RMB 18.00 per share[75]. - The total amount spent on the share repurchase was RMB 400,032,878.38, including transaction fees[75]. - The company plans to use repurchased shares for the conversion of issued convertible bonds, with a deadline for implementation within 12 months from the approval date[74]. Market Strategy - The company aims to adjust its product structure and marketing strategies to mitigate the adverse effects of potential regional COVID-19 outbreaks on sales[51]. - The company plans to enhance its product market competitiveness and core capabilities in response to regulatory changes in the pharmaceutical industry[50].